Skip to Content

DaVita Inc

DVA: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$981.00XtbswlBkcvkhyl

Raising DaVita's Uncertainty Rating After Supreme Court Ruling

Business Strategy and Outlook

After selling the DaVita Medical Group in 2019, DaVita focuses almost exclusively on providing services to end-stage renal disease, or ESRD, patients primarily in the United States with an expanding international footprint. Over several decades, DaVita has built the largest network of dialysis clinics in the U.S., and although COVID-19-related mortality concerns look likely to constrain results through 2022, we view DaVita's long-term prospects as solid.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of DVA so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center